Development of Selective Low-Density Lipoprotein (LDL) Apheresis System: Immobilized Polyanion as LDL-Specific Adsorption for LDL Apheresis System
- 1 August 1996
- journal article
- Published by Wiley in Artificial Organs
- Vol. 20 (8), 922-929
- https://doi.org/10.1111/j.1525-1594.1996.tb04571.x
Abstract
Low-density lipoprotein (LDL) is widely recognized as one of the major risk factors for developing coronary heart diseases. Despite intensive development of LDL-lowering drugs, there still exist those patients with refractory hyperlipidemia whose plasma LDL levels are not sufficiently lowered by drugs. LDL apheresis, direct removal of plasma LDL from circulating blood, is thought to be the most promising treatment for such refractory patients. Various techniques, such as the use of an immunoadsorbent utilizing an anti-LDL antibody, have been used in an attempt to achieve the selective removal of LDL. However, none were widely used because of complications, poor selectivity, and so forth. To establish a safe and effective LDL apheresis system, we chose a synthetic affinity adsorbent as the LDL-removing device. Synthetic polyanion compounds were used as the affinity ligands for LDL adsorbent to simulate the anion-rich sequence of LDL binding sites in the human LDL receptor. Among various polyanion compounds, those polyanions with sulfate or sulfonate groups and hydrophilic backbone were found to have strong affinity for LDL. In contrast, polyanions with carboxyl groups showed poor affinity. Dextran sulfate (DS) was selected as the affinity ligand of LDL adsorbent for its high affinity and low toxicity. The influence of its charge density and molecular weight on its affinity for LDL was suitable. The affinity rapidly increased as the charge density increased, then, reached a constant value. Little affinity was found for either the DS monomer (glucose sulfate) or DS with a molecular weight higher than 10(4) daltons whereas DS with molecular weights in the midrange showed strong affinity. DS with a midrange molecular weight was immobilized on cellulose hard gel to give LDL adsorbent clinical application. The adsorbent demonstrated an excellent selectivity for LDL and very low density lipoprotein (VLDL) in vitro. Adsorption of high-density lipoprotein and major plasma proteins was almost negligible. Additional study of the LDL-binding mechanism revealed that DS directly interacts with positively charged sites on LDL, which demonstrates that the nature of the interaction is the same as that of LDL receptor. An LDL adsorption column (Liposorber) packed with an LDL adsorbent and polysulfone hollow-fiber plasma separator (Sulflux) was developed as an efficient LDL apheresis system. Clinical investigation proved that this system is capable of intensively lowering the plasma LDL level without affecting major plasma components.Keywords
This publication has 16 references indexed in Scilit:
- Selective removal of low density lipoproteins (LDL) by precipitation at low pH: First clinical application of the HELP systemKlinische Wochenschrift, 1987
- Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange.BMJ, 1985
- Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985
- Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- APPLICATION OF SPECIFIC EXTRACORPOREAL REMOVAL OF LOW DENSITY LIPOPROTEIN IN FAMILIAL HYPERCHOLESTEROLAEMIAThe Lancet, 1981
- Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma.Proceedings of the National Academy of Sciences, 1981
- Assessment of long-term plasma exchange for familial hypercholesterolaemia.Heart, 1980
- PLASMA EXCHANGE IN THE MANAGEMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLÆMIAThe Lancet, 1975
- Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart DiseaseAnnals of Internal Medicine, 1971